Improved access to HIV diagnosis and linkage to antiretroviral therapy among children in Southern Nigeria: a before-after study.
Case Identification, Linkage, Anti-Retroviral therapy
Children, Orphaned
HIV infection
Nigeria
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
20 05 2023
20 05 2023
Historique:
received:
27
07
2022
accepted:
29
04
2023
medline:
22
5
2023
pubmed:
21
5
2023
entrez:
20
5
2023
Statut:
epublish
Résumé
Globally, two out of five children living with HIV (CLHIV) are unaware of their HIV status, and a little more than 50% are receiving antiretroviral therapy (ART). This paper describes case-finding strategies and their contribution to identifying CLHIV and linking them to ART in Nigeria. This before-after study used program data abstracted during the implementation of different paediatric-focused strategies (provider-initiated testing and counselling, orphans and vulnerable children testing, family-based index testing, early infant diagnosis (EID), community-driven EID, and community-based testing) delivered in health facilities and in communities to improve HIV case identification. Data were abstracted for children (0 to 14 years) who received HIV testing services and were initiated on ART in Akwa Ibom State, Nigeria during the pre-implementation period (April-June 2021) and during the implementation period (July-September 2021). Descriptive statistics were used to describe the testing coverage, positivity rate (proportion of tests that were positive for HIV), linkage to ART, and ART coverage, by age, sex, and testing modality. Interrupted time series analysis (ITSA) on STATA 14 was used to estimate the effect of the implementation of these strategies on HIV testing uptake and positivity rate at a 0.05 significance level. A total of 70,210 children were tested for HIV within the six-month period, and 1,012 CLHIV were identified. A total of 78% (n = 54,821) of the tests and 83.4% (n = 844) CLHIV were diagnosed during the implementation period. During implementation, the HIV positivity rate increased from 1.09% (168/15,389) to 1.54% (844/54,821), while linkage to ART increased from 99.4% (167/168) to 99.8% (842/844). The contribution from community-based modalities to CLHIV identified increased from 63% (106/168) to 84% (709/844) during the implementation, with the majority, 60.8% (431/709), from community-based index testing. Overall, ART coverage increased from 39.7 to 55.6% at the end of the intervention period. The findings show that expanding differentiated HIV testing approaches provided mostly in the community significantly increased pediatric case identification. However, ART coverage remains low, especially for younger age groups, and requires further efforts.
Sections du résumé
BACKGROUND
Globally, two out of five children living with HIV (CLHIV) are unaware of their HIV status, and a little more than 50% are receiving antiretroviral therapy (ART). This paper describes case-finding strategies and their contribution to identifying CLHIV and linking them to ART in Nigeria.
METHODS
This before-after study used program data abstracted during the implementation of different paediatric-focused strategies (provider-initiated testing and counselling, orphans and vulnerable children testing, family-based index testing, early infant diagnosis (EID), community-driven EID, and community-based testing) delivered in health facilities and in communities to improve HIV case identification. Data were abstracted for children (0 to 14 years) who received HIV testing services and were initiated on ART in Akwa Ibom State, Nigeria during the pre-implementation period (April-June 2021) and during the implementation period (July-September 2021). Descriptive statistics were used to describe the testing coverage, positivity rate (proportion of tests that were positive for HIV), linkage to ART, and ART coverage, by age, sex, and testing modality. Interrupted time series analysis (ITSA) on STATA 14 was used to estimate the effect of the implementation of these strategies on HIV testing uptake and positivity rate at a 0.05 significance level.
RESULTS
A total of 70,210 children were tested for HIV within the six-month period, and 1,012 CLHIV were identified. A total of 78% (n = 54,821) of the tests and 83.4% (n = 844) CLHIV were diagnosed during the implementation period. During implementation, the HIV positivity rate increased from 1.09% (168/15,389) to 1.54% (844/54,821), while linkage to ART increased from 99.4% (167/168) to 99.8% (842/844). The contribution from community-based modalities to CLHIV identified increased from 63% (106/168) to 84% (709/844) during the implementation, with the majority, 60.8% (431/709), from community-based index testing. Overall, ART coverage increased from 39.7 to 55.6% at the end of the intervention period.
CONCLUSION
The findings show that expanding differentiated HIV testing approaches provided mostly in the community significantly increased pediatric case identification. However, ART coverage remains low, especially for younger age groups, and requires further efforts.
Identifiants
pubmed: 37210497
doi: 10.1186/s12887-023-04050-w
pii: 10.1186/s12887-023-04050-w
pmc: PMC10199424
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Subventions
Organisme : PEPFAR
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2021 Mar 25;16(3):e0248751
pubmed: 33765053
BMC Pediatr. 2018 Aug 3;18(1):259
pubmed: 30075712
J Int AIDS Soc. 2012 Feb 22;15(1):8
pubmed: 22353553
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S88-S97
pubmed: 29994830
PLoS One. 2019 May 6;14(5):e0214251
pubmed: 31059507
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):352-357
pubmed: 29995704
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S107-S114
pubmed: 29994832
PLoS One. 2019 Jul 31;14(7):e0220616
pubmed: 31365571
PLoS One. 2021 May 6;16(5):e0251247
pubmed: 33956881
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):e83-e89
pubmed: 27846074
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):421-426
pubmed: 33764965
PLoS One. 2020 Jun 17;15(6):e0234079
pubmed: 32555584
PLoS One. 2019 Mar 27;14(3):e0212762
pubmed: 30917167
Curr Opin HIV AIDS. 2017 Mar;12(2):112-116
pubmed: 27941493
BMC Health Serv Res. 2020 May 6;20(1):385
pubmed: 32375752
PLoS One. 2020 Sep 2;15(9):e0236985
pubmed: 32877441
BMC Pediatr. 2021 Jan 12;21(1):33
pubmed: 33435898
Lancet HIV. 2021 Mar;8(3):e138-e148
pubmed: 33197393
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):78-85
pubmed: 28991881
AIDS Care. 2022 Feb;34(2):250-262
pubmed: 33813954
Public Health Action. 2019 Sep 21;9(3):128-134
pubmed: 31803585
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S98-S106
pubmed: 29994831
Int J MCH AIDS. 2021;10(2):210-220
pubmed: 34938594